Form 4: Akero Therapeutics CEO Andrew Cheng Sells Shares to Cover Tax Obligations
SEC Form 4 Filing
Akero Therapeutics CEO Andrew Cheng sold 1,738 shares of common stock on March 12, 2025, to cover tax withholding obligations related to vesting restricted stock units.
Summary
- On March 12, 2025, Andrew Cheng, the President and CEO of Akero Therapeutics, sold 1,738 shares of Akero Therapeutics (AKRO) common stock.
- The sale was executed at a price of $44.88 per share.
- This transaction was conducted to cover tax withholding obligations associated with the vesting of restricted stock units.
- Following the transaction, Andrew Cheng directly owns 654,324 shares of Akero Therapeutics.
- The sale was automatic and not at the discretion of the Reporting Person, according to the document.
Sentiment
Score: 5
Explanation: The document describes a routine transaction (stock sale for tax obligations) and doesn't indicate any significant positive or negative sentiment.
Industry Context
Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. This particular filing reflects a common practice of executives selling shares to cover tax obligations related to equity compensation.
Stakeholder Impact
- The sale of shares by the CEO could have a minor impact on shareholder sentiment, but is unlikely to be significant given the reason for the sale.
Key Dates
| Date | Description |
|---|---|
| 03/12/2025 | Date of stock sale transaction |
| 03/14/2025 | Date of signature on the Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.